Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ci-1040. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 known ✓ | Q02750 | 17/20 | 1.00 |
| ▸ | MAP2K2 known ✓ | P36507 | 7/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | CSNK2B | P67870 | 1/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 1.00 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 1.00 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 1.00 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.57 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.57 |
| ▸ | BRAF | P15056 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ci-1040 SCHEMBL29381365 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| Ci-1040 SCHEMBL29355105 | 1.00 | MAP2K1 (1.00) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL5389070 | 0.96 | MAP2K1 (0.93) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL4750937 | 0.91 | MAP2K1 (0.83) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL16706486 | 0.90 | MAP2K1 (0.82) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL5389799 | 0.90 | MAP2K1 (0.82) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL18088593 | 0.90 | MAP2K1 (0.82) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| Ci-1040 SCHEMBL7787490 | 0.89 | MAP2K1 (0.80) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL5388101 | 0.89 | MAP2K1 (0.80) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 | |
| SCHEMBL19263460 | 0.89 | MAP2K1 (0.80) | MAP2K1MAP2K2RAF1PDGFRBCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1071 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195771-B2 | Combination chemotherapy for the treatment of cancer | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-01-14 | — | — | US | claimed |
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2024-08-01 | — | — | US | claimed |
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| US-20220195408-A1 | COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF CANCER | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2022-06-23 | — | — | US | claimed |
| US-20210187013-A1 | Methods of Treating and Preventing Cancer by Disrupting the Binding of Copper in the Map Kinase Pathway | DUKE UNIVERSITY (US) | 2021-06-24 | — | — | US | claimed |
| US-10675331-B2 | Method for achieving desired glial growth factor 2 plasma levels | ACORDA THERAPEUTICS, INC. (US) | 2020-06-09 | — | — | US | claimed |
| EP-3632208-A1 | CELL STABILIZATION | Biomatrica, INC. (US) | 2020-04-08 | — | — | EP | claimed |
| EP-3031908-B1 | METHOD FOR PRODUCING DOPAMINERGIC NEURONS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-05 | — | — | EP | claimed |
| US-10017734-B2 | Method for producing dopaminergic neurons | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | claimed |
| WO-2001005392-A2 | METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| WO-2000037141-A9 | COMBINATION CHEMOTHERAPY | WARNER LAMBERT CO (US) | 2000-12-07 | — | — | WO | claimed |
| WO-2000040237-A1 | ANTIVIRAL METHOD USING MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2000040235-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2000037141-A1 | COMBINATION CHEMOTHERAPY | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| WO-2000035435-A1 | USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| WO-2000035436-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| EP-0993439-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-04-19 | — | — | EP | claimed |
| WO-1999001426-A1 | 4-BROMO OR 4-IODO PHENYLAMINO BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-01-14 | — | — | WO | claimed |
| WO-1998037881-A1 | METHOD OF TREATING OR PREVENTING SEPTIC SHOCK BY ADMINISTERING A MEK INHIBITOR | WARNER LAMBERT COMPANY (US) | 1998-09-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252454-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | TFAM, POLRMT, TUFM | MAP2K1 4052/4885MAP2K2 3644/4885RAF1 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.